文献

PA007512.m1：体内实验级重组抗小鼠/人/大鼠/猴/仓鼠/犬/牛TGF-beta单克隆抗体(克隆号1D11.16.8)，小鼠IgG1 kappa

体内实验级重组抗小鼠/人/大鼠/猴/仓鼠/犬/牛TGF-beta单克隆抗体(克隆号1D11.16.8) 是一种能广谱中和三种主要异构体（TGF-β1、TGF-β2和TGF-β3）的泛种属特异性阻断抗体。TGF-β作为关键的多功能抑制性细胞因子，在肿瘤免疫逃逸、免疫微环境重塑、抑制T细胞与NK细胞功能以及器官纤维化发生发展中扮演着核心角色。克隆号1D11.16.8抗TGF-beta单克隆抗体具备极高的跨种属交叉反应性，可特异性结合小鼠、人、大鼠、非人灵长类（猴）、仓鼠、犬及牛等多种哺乳动物的TGF-β蛋白，有效阻断下游Smad及非Smad信号通路的激活，在肿瘤免疫治疗、器官纤维化（如肺/肝/肾纤维化）及自身免疫性疾病的机理探索中发挥着不可替代的作用。

体内实验级重组抗小鼠/人/大鼠/猴/仓鼠/犬/牛TGF-beta单克隆抗体(克隆号1D11.16.8)，小鼠IgG1 kappa 采用基因工程技术由哺乳动物细胞重组表达，搭配小鼠IgG1 Kappa恒定区骨架，具有优异的批间一致性与低免疫原性，极适合长期的动物体内（in vivo）功能性实验。产品生产过程严格把控，具备超低内毒素、无防腐剂及无载体蛋白等高纯度特性，可有效避免内毒素引发的非特异性炎症干扰。在同系移植肿瘤模型和各类纤维化疾病模型中，该抗体广泛应用于体内TGF-β信号通路的靶向阻断，也是研究TGF-β阻断剂与PD-1/PD-L1等免疫检查点抑制剂联合给药协同抗肿瘤疗效的标准工具抗体。

抗小鼠/人/大鼠/猴/仓鼠/犬/牛 TGF-beta 单克隆抗体（克隆号：1D11.16.8）参考文献：

1. Transforming Growth Factor-β and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals

Komai, T., et al. Front Immunol. 2018 Jun 14;9:1364. PMID: 29963056

“Inhibitory cytokines like transforming growth factor-β (TGF-β) and interleukin-10 (IL-10) are key regulators of immune homeostasis, as mice deficient for either of these regulatory cytokines develop severe inflammatory diseases. Blockade of pro-inflammatory cytokines offers effective treatment of inflammatory autoimmune diseases such as rheumatoid arthritis. …The effects of representative inhibitory cytokines, TGF-β, and IL-10, on B cells have been examined. …Anti-IL-10 mAb (300 μg) (JES5-2A5, Bio X Cell, West Lebanon, NH, USA) and 300 μg anti-TGF-β antibody (1D11.16.8, Bio X Cell) were administered i.p. at day -1, 2, and 5.”

2. TGF-β Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia

Greco, S. H., et al. PLoS One. 2015 Jul 14;10(7):e0132786. PMID: 26172047

“Potential immunologic targets for cachexia treatment in PDA, include Toll-like receptors (TLRs) and transforming growth factor beta (TGF-β). …The transforming growth factor beta (TGF-β) pathway plays an important role in cell differentiation and inflammation. …However, at the same time TGF-β blockade may reduce the invasiveness of PDA. …For immunohistochemical analysis, paraffin-embedded tissue sections were stained using polyclonal anti-TGF-β (1:100; Abcam, Cambridge, MA), anti-p21 (1:100, Santa Cruz), or anti p-Smad 2/3 (1:50, Santa Cruz) and the corresponding isotype controls. …Collectively, these data suggest that targeting TGF-β is an attractive strategy for targeting pancreatic cancer cachexia.”

3. Loss of the TGF-β-activating integrin αvβ8 on dendritic cells protects mice from chronic intestinal parasitic infection via control of type 2 immunity

Worthington, J. J., et al. PLoS Pathog. 2013;9(10):e1003675. PMID: 24098124

“Using a model parasite which infects mice, we find that a protein called transforming growth factor beta (TGF-β) signals to T-cells early during the development of chronic infection and that blocking this signal protects mice from infection. …We have also uncovered a key pathway and cell type that controls TGF-β function during development of chronic infection. …A key cytokine that plays a multi-functional role in controlling immune responses is transforming growth factor beta (TGF-β). …Given its importance in regulating diverse T-cell responses, it is not surprising that TGF-β plays a crucial role in the maintenance of immune homeostasis and prevention of autoimmunity. …However, the function of TGF-β during helminth infection and how it is regulated to control immune responses to intestinal parasites is poorly understood.”

Syd Labs抗小鼠/人/大鼠/猴/仓鼠/犬/牛TGF-beta单克隆抗体(克隆号1D11.16.8)，小鼠IgG1 kappa（货号：PA007512.m1）推荐同型对照抗体:

重组小鼠IgG1同型对照抗体